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CASO CLINICO 
Mulher, 45 anos, raça negra. 
 
Antecedentes pessoais: 
.HTA há 4 anos, não controlada 
.Cirurgia hernia inguinal 
 
Antecedentes familiares: irrelevantes 
 
Medicação habitual:IECA.  
 
Alergias:  
Sindroma “gripal” 
Hb 10.6 Plaq 135 000 
urina II: Hb 1+ prot 100 
 
Alta: Paracetamol, 
fosfomicina,  
10.11.12 16.11.12 
Diarreia aquosa, 
vómitos e dor 
abdominal 
14.11.12 
PA 226-136 mm Hg T 36.4 º C  
 sobrecarga de volume;  
lesões cutâneas,  discrasia 
hemorrágica, défices 
neurológicos,  sinais meníngeos 
Lab: 
Hb 11.5 g/dl Plaq 127 000 Leuc N 
sCr 6.5 mg/dl ureia 89 mg/dl Bicarb 
22 mmol/L Urina II: prot 100 Hb 1+ 
LDH 869 /L BilT 1.7 g/dl  
Ecografia renal: 95 x98 
mm;  ecogenecidade 
 
D 3 
Lab: 
Hb 8.9 g/dl Plaq 112 000 Leuc N 
sCr 9.05 mg/dl ureia116 mg/dl  
ceftriaxone  
Haptoglobina < 7, bilirrubina N 
esquizócitos sangue periférico 
Coombs negativo. 
Anemia hemolítica microangiopática + 
trombocitopenia + lesão orgão 
 
Microangiopatia trombótica 
Indução HD 
   
 
Diagnóstico Diferencial 


Exames Complementares Diagnóstico 
• Fundoscopia: exsudados algodonosos, sem edema 
da papila (grau III). 
• Estudo HTA secundária negativa. 
• TP e aPTT normais. 
• C3  C4 N; ANA, dsDNA negativo; ANCA negativo 
• Serologias HIV, HCV, HBV negativas. IgM CMV, 
adenovirus, HSV negativa 
• Coproculturas negativas;  
• Hemoculturas negativas. 
 
 
 
 
Biópsia renal: 
-infiltrado intersticial e glomerular 
exuberante; 
-trombos intracapilares e edema 
endotelial  
IF: C3 na IF 
 
1.Plasmaferese 1.5 V x 5 
sessões substituição PFC 
2. HD 
 
D 5 
Estudo genético: 
Mutação no gene CHF 
 
Suspendeu HD após 18 
dias. 
 Alta  
sCr 4.14 mg/dl RAC 3 
 
D 32 
Intimal oedema arteriole. 
(Trichrome) 
Global capillary oedema Double contours (Jones’s 
silver) 
Intimal insudation and 
erythrocytic infiltration of 
arteriole 
Fibrinoid necrosis of 
arteriole (Trichrome) 
Severe reduction of 
arteriolar lumen, intimal 
oedema 
Oedema and erythrocyte 
in GCW 
Global ischemic collapse. 
(PAS) 
Patients Mutações Clinica 
CFH MCP CFI CFB C3 Admissão Último FU Outcome 
GFR 
(ml/min) 
HUS_IF 08-07-01 18-09-01 
HUS 
Dead 
CRRT 
HUS127 
c.89insA 
c.178T>C 
-- -- -- -- 05-12-05 28-10-12 CKD5 D RRT 
HUS128 -- -- -- -- -- 25-03-03 26-11-13 
Partial 
recovery 
40 
HUS129 -- -- -- -- -- 26-01-02 21-03-14 
Total 
recovery 
110 
HUS143 c.89insA c.623T>C -- -- -- 02-11-2003 28-03-14 2º HUS 2012 38 
HUS143_P1 c.89insA c.623T>C -- -- -- 01-10-2005 29-04-14 2º HUS 2010 49 
HUS352 c.3469T>C -- -- -- -- 10-11-2012 06-10-2014 
GNC3 
Eculizumab 
40 
HUS_C c.493 G>T -- 14-8-14 21-10-14 
Partial 
recovery 
17 
C3_HUS 28-8-13 12-5-14 
HUS 
Dead 
RRT 
SHUa  Serviço de Nefrologia HFF 
Evolução 
Out 
2013 
sCr 2.7 mg/dl CKD EPI 23 ml/min 
RAC 0.7 sem hematuria 
Hb 11.7 g/dl plaquetas N LDH N 
 
 
Jan 
2014 
sCr 3.9 mg/dl RAC 1 hematuria  
Hb 10.0 g/dl haptoglobina   
HTA 
 2ª biopsia:  
-Esclerose 6/15 gl 
-Hipercelularidade mesangial MN 
-Infiltrado intersticial intenso 30% 
-IF: C3 
Fev 
2014 
Eculizumab 7 ciclos  
até 08/14  
Maio 
2014 
Out 
2014 
sCr 2.9 mg/dl RAC 0.4 
Hb 12.7 haptoglobina N 
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Use of eculizumab for atypical haemolytic 
uraemic syndrome and C3 glomerulopathies
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Abstract | In the past decade, a large body of evidence has accumulated in support of the critical role of 
dysregulation of the alternative complement pathway in atypical haemolytic uraemic syndrome (aHUS) and 
C3 glomerulopathies. These findings have paved the way for innovative therapeutic strategies based on 
complement blockade, and eculizumab, a monoclonal antibody targeting the human complement component 5, 
is now widely used to treat aHUS. In this article, we review 28 case reports and preliminary data from 37 
patients enrolled in prospective trials of eculizumab treatment for episodes of aHUS involving either native 
or transplanted kidneys. Eculizumab may be considered as an optimal first-line therapy when the diagnosis 
of aHUS is unequivocal and this treatment has the potential to rescue renal function when administered 
early after onset of the disease. However, a number of important issues require further study, including the 
appropriate duration of treatment according to an individual’s genetic background and medical history, the 
optimal strategy to prevent post-transplantation recurrence of aHUS and a cost–efficacy analysis. Data 
regarding the efficacy of eculizumab in the control of C3 glomerulopathies are more limited and less clear, but 
several observations suggest that eculizumab may act on the most inflammatory forms of this disorder.
Zuber, J. et al. Nat. Rev. Nephrol. 8, 643–657 (2012); published online 2 October 2012; doi:10.1038/ nrneph.2012.214
Int roduct ion 
Atypical haemolytic uraemic syndrome (aHUS) and 
the C3 glomerulopathies are two ultra-rare kidney 
diseases that are recognized as complement-mediated 
conditions characterized by overactivation of the alter-
native complement pathway.1,2 During the past decade, 
an increasing number of mutations in genes coding for 
proteins involved in the formation or regulation of the 
alternative pathway C3 convertase complex have been 
reported to be associated with aHUS.2,3 aHUS is there-
fore emerging as a paradigm of disease caused by the 
inefficient protection of the endothelium from comple-
ment attack. C3 convertase dysregulation induces exces-
sive cleavage of C3, and subsequent excessive cleavage 
of C5, leading to endothelial cell damage, which trig-
gers platelet recruitment and thrombus formation in 
the kidney microvasculature.4 Although uncontrolled 
complement activation is involved in the pathogenesis 
of both C3 glomerulopathies and of aHUS, the com-
plement dysregulation in C3 glomerulopathies takes 
place in the fluid phase, rather than on the surface of 
the endothelium, and leads to C3 being released into 
the bloodstream and deposited in the kidney.5,6 To date, 
genetic abnormalities identified in patients with aHUS 
and C3 glomerulopathies have involved components of 
the alternative pathway, including complement factor H 
(CFH), complement factor I (CFI), membrane cofactor 
protein (MCP), complement factor B (CFB) and comple-
ment component 3 (C3). Although both diseases involve 
overactivation of the alternative complement pathway 
and although both lack an effective therapy, substantial 
differences have been noted between the mechanism of 
aHUS, which primarily involves the terminal activation 
of C5b–9, and that of C3 glomerulopathies, in which C3 
split products have been shown to have a pathogenic 
role.7 Breakthroughs in our understanding of the patho-
genesis of aHUS have coincided with the availability of 
an innovative drug, eculizumab, which is an inhibitor of 
the terminal complement pathway.8,9 Eculizumab can be 
considered the standard of care for the treatment of par-
oxysmal nocturnal haemoglobinuria (PNH) and its use 
has so far been associated with only one major adverse 
effect, an increased risk of meningococcal infection.10–13
During 2012, eculizumab has begun to emerge as the 
new targeted disease-modifying treatment for aHUS and 
in the near future it might also be used for the treatment 
of some types of C3 glomerulopathy.
Funct ional effects of eculizumab 
Eculizumab is a recombinant, fully humanized hybrid 
IgG2/IgG4 monoclonal antibody directed against human 
complement component C5. The drug has been engi-
neered to minimize immunogenicity and Fc-mediated 
functions, including recruitment of inflammatory cells 
and complement activation (Figure 1a). Normal C5 
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Introduction 
Atypical haemolytic uraemic syndrome (aHUS) and 
the C3 glomerulopathies are two ultra-rare kidney 
diseases that are recognized as complement-mediated 
conditions characterized by overactivation of the alter-
native complement pathway.1,2 During the past decade, 
an increasing number of mutations in genes coding for 
proteins involved in the formation or regulation of the 
alternative pathway C3 convertase complex have been 
reported to be associated with aHUS.2,3 aHUS is there-
fore emerging as a paradigm of disease caused by the 
inefficient protection of the endothelium from comple-
ment attack. C3 convertase dysregulation induces exces-
sive cleavage of C3, and subsequent excessive cleavage 
of C5, leading to endothelial cell damage, which trig-
gers platelet recruitment and thrombus formation in 
the kidney microvasculature.4 Although uncontrolled 
complement activation is involved in the pathogenesis 
of bot  C3 gl merulopathies and of aHUS, the com-
plement dysregulation in C3 glomerulopathies takes 
place in the fluid phase, rather than on the surface of 
the endothelium, and leads to C3 being released into 
the bloodstream and deposited in the kidney.5,6 To date, 
genetic abnormalities identified in patients with aHUS 
and C3 glomerulopathies have involved components of 
the alternative pathway, including complement factor H 
(CFH), complement factor I (CFI), membrane cofactor 
protein (MCP), complement factor B (CFB) and comple-
ment component 3 (C3). Although both diseases involve 
overactivation of the alternative complement pathway 
and although both lack an effective therapy, substantial 
differences have been noted between the mechanism of 
aHUS, which primarily involves the terminal activation 
of C5b–9, and that of C3 glomerulopathies, in which C3 
split products have been shown to have a pathogenic 
role.7 Breakthroughs in our understanding of the patho-
genesis of aHUS have coincided with the availability of 
an innovative drug, eculizumab, which is an inhibitor of 
the terminal complement pathway.8,9 Eculizumab can be 
considered the standard of care for the treatment of par-
oxysmal nocturnal haemoglobinuria (PNH) and its use 
has so far been associated with only one major adverse 
effect, an increased risk of meningococcal infection.10–13
During 2012, eculizumab has begun to emerge as the 
new targeted disease-modifying treatment for aHUS and 
in the near future it might also be used for the treatment 
of some types of C3 glomerulopathy.
Functional effects of eculizumab 
Eculizumab is a recombinant, fully humanized hybrid 
IgG2/IgG4 monoclonal antibody directed against human 
complement component C5. The drug has been engi-
neered to minimize immunogenicity and Fc-mediated 
functions, including recruitment of inflammatory cells 
and complement activation (Figure 1a). Normal C5 
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Introduct ion 
Atypical haemolytic uraemic syndrome (aHUS) and 
the C3 glomerulopathies are two ultra-rare kidney 
diseases that are recognized as complement-mediated 
conditions characterized by overactivation of the alter-
native complement pathway.1,2 During the past decade, 
an increasing number of mutations in genes coding for 
proteins involved in the formation or regulation of the 
alternative pathway C3 convertase complex have been 
reported to be associated with aHUS.2,3 aHUS is there-
fore emerging as a paradigm of disease caused by the 
inefficient protection of the end thelium from comple-
ment attack. C3 convertase dysregulation induces exces-
sive cleavage of C3, and subsequent excessive cleavage 
of C5, leading to endothelial cell damage, which trig-
gers platelet recruitment and thrombus formation in 
the kidney microvasculature.4 Although uncontrolled 
complement activation is involved in the pathogenesis 
of both C3 glomerulopathies and of aHUS, the com-
plement dysregulation in C3 glomerulopathies takes 
place in the fluid phase, rather than on the surface of 
the endothelium, and leads to C3 being released into 
the bloodstream and deposited in the kidney.5,6 To date, 
genetic abnormalities identified in patients with aHUS 
and C3 glomerulopathies have involved components of 
the alternative pathway, including complement factor H 
(CFH), complement factor I (CFI), membrane cofactor 
protein (MCP), complement factor B (CFB) and comple-
ment component 3 (C3). Although both diseases involve 
overactivation of the alternative complement pathway 
and although both lack an effective therapy, substantial 
differences have been noted between the mechanism of 
aHUS, which pri arily involves the terminal activation 
of C5b–9, and that of C3 glomerulopathies, in which C3 
split products have been hown to have a pathogenic 
role.7 Breakthroughs in ur und rstandi g of the patho-
genesis of aHUS ave coincided with the availability of 
an innovative drug, eculizumab, which is an inhibitor of 
theterminal complement pathway.8,9 Eculizumab can be 
consider d the standar  of care f r the treatment of par-
oxysmal nocturnal emoglobinuria (PNH) and its use 
has so far been associated with only one major adverse 
effect, an increased risk of meningococcal infection.10–13
During 2012, eculizumab has begun to e erge as the 
new targeted disease-modifying treatment for aHUS and 
in the near future it might also be used for the treatment 
of some types of C3 glomerulopathy.
Funct ional effects of eculizumab 
Eculizumab is a recombinant, fully humanized hybrid 
IgG2/IgG4 monoclonal antibody directed against human 
complement component C5. The drug has been engi-
neered to minimize immunogenicity and Fc-mediated 
functions, including recruitment of inflammatory cells 
and complement activation (Figure 1a). Normal C5 
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